Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary...

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Optimal clopidogrel loading dose in chronic kidney disease (CKD) patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) remains unestablished.
• CKD is associated with increased risks of adverse cardiovascular events and bleeding.

Purpose of the Study:

• To evaluate the impact of a 600 mg versus 300 mg clopidogrel loading dose on clinical outcomes in CKD patients undergoing primary PCI for STEMI.

Main Methods:

• A retrospective analysis of 1,457 CKD patients (eGFR <60 ml/min/1.73 m²) who received either a 600 mg (n=861) or 300 mg (n=596) clopidogrel loading dose.
• Comparison of in-hospital complications, major bleeding, and major adverse cardiac events (MACE) at 1 and 12 months between the two groups.
• Multivariate and propensity score-matched analyses were performed.

Main Results:

• In-hospital major bleeding rates were similar between the 600 mg and 300 mg groups (0.8% vs 0.2%, p=0.09).
• No significant differences in MACE rates (death, recurrent MI, target lesion revascularization, stent thrombosis) were observed at 1 month (15.6% vs 16.4%, p=0.70) and 12 months (19.0% vs 21.3%, p=0.32).
• The 600 mg loading dose was not an independent predictor of MACE at 1 or 12 months in multivariate analysis.

Conclusions:

• A 600 mg clopidogrel loading dose is not effective in reducing MACE in CKD patients undergoing primary PCI for STEMI.
• The higher loading dose did not increase the risk of in-hospital major bleeding in this patient population.
• Current evidence suggests that standard dosing may be sufficient for CKD patients undergoing primary PCI for STEMI.